Human T regulatory cell therapy: take a billion or so and call me in the morning.
Human T regulatory cell therapy: take a billion or so and call me in the morning.
复制标题
DOI：
10.1016/j.immuni.2009.04.006
复制
发表时间：
2009-05
期刊：
影响因子：
32.4
通讯作者：
Blazar, Bruce R.
中科院分区：
文献类型：
--
作者：
Riley, James L.;June, Carl H.;Blazar, Bruce R.
免疫系统的调节对宿主的生存至关重要。在自身免疫和同种异体免疫的情况下，失去控制，导致重要器官和组织的损伤。表达CD4、CD25和叉头盒蛋白3（FoxP3）的天然存在的胸腺源性调节性T细胞（T细胞）是这些不良免疫应答的有效抑制剂。临床前研究表明，无论是新鲜分离或体外扩增的THBE可以防止局部和全身器官和组织的破坏。尽管有希望，但迄今为止，人Treg输注疗法难以在临床中实施，并且已经启动了相对较少的临床试验。本综述将重点介绍为当前试验提供理论基础的临床前模型，并将讨论人类Treg治疗的挑战和机遇。
Immune system regulation is of paramount importance to host survival. In settings of autoimmunity and alloimmunity, control is lost, resulting in injury to vital organs and tissues. Naturally occurring, thymic-derived T regulatory cells (Tregs) that express CD4, CD25 and the forkhead box protein 3 (FoxP3) are potent suppressors of these adverse immune responses. Preclinical studies have shown that either freshly isolated or ex vivo expanded Tregs can prevent both local and systemic organ and tissue destruction. Although promising, human Treg infusion therapy has heretofore been difficult to implement in the clinic, and relatively few clinical trials have been initiated. This review will focus on the preclinical models that provide the rationale for current trials and it will address both the challenges and opportunities in human Treg therapy.
登录
查看更多内容
影响因子：
46.9
作者：
Azuma, Hisaya;Paulk, Nicole;Grompe, Markus
通讯作者：
Grompe, Markus
影响因子：
32.4
作者：
Fontenot, JD;Rasmussen, JP;Rudensky, AY
通讯作者：
Rudensky, AY
DOI：
10.1084/jem.20051060
发表时间：
2005-08-01
期刊：
The Journal of experimental medicine
影响因子：
--
作者：
通讯作者：
--
影响因子：
20.3
作者：
Godfrey, WR;Spoden, DJ;Porter, SB
通讯作者：
Porter, SB
影响因子：
12.8
作者：
Ansari, Aftab A.;Pereira, Lara E.;Villinger, F.
通讯作者：
Villinger, F.